Skip to main content
. 2015 Mar 17;172(9):2369–2382. doi: 10.1111/bph.13062

Figure 7.

Figure 7

Effects of pimobendan on contraction and CaT in single cardiomyocytes isolated from DCM mice in different stages of HF. (A) Representative SL shortening and CaT in a single cardiomyocytes isolated from DCM mice in compensated or end-stage HF, which are perfused with Krebs–Henseleit solution containing 0, 3 and 10 μM pimobendan. (B) Effects of cilostazol (30 μM) on SL shortening and CaT in single cardiomyocytes isolated from end-stage HF DCM mice. (C) Effects of pimobendan on phosphorylation of cTnI at Ser22/23 in isolated cardiomyocytes (n = 3 hearts per group). **P < 0.01; significantly different as indicated; one-way anova and post hoc Tukey's multiple comparison. (D) Effects of verapamil (3 μM) on SL shortening and CaT in a single cardiomyocytes isolated from end-stage HF DCM mice, which is perfused with Krebs–Henseleit solution containing 10 μM pimobendan. (E) Percentage of cardiomyocytes showing triggered activity in investigated cardiomyocytes of end-stage HF DCM mice.